RECCE PHARMACEUTICALS LTD — Capital/Financing Update 2026

Jan 13, 2026

ASX Announcement

==> picture [416 x 93] intentionally omitted <==

AUD $5.3m R&D Rebate Received

SYDNEY Australia, 14 January 2026: Recce Pharmaceuticals Ltd ( ASX: RCE , FSE: R9Q ) (the Company ), the Company developing a new class of Synthetic Anti-infectives, is pleased to announce cash refund of AUD $5,339,202 Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for the financial year ending 30 June 2025.

The AUD $5,339,202 reflects R&D activities undertaken locally and overseas, provided to the Company in cash, without caveat.

The Australian Government’s 43.5% Research & Development Tax Incentive rebate, supports Australian innovation, providing expanded benefit to the Company by allowing it to capture 43.5% of the Company’s R&D applicable activities, undertaken anywhere in the world.

As undertaken in previous financial years, the Company has lodged a further R&D Tax Incentive submission in respect of additional eligible activities. Subject to review and approval by the Australian Taxation Office, the Company expects a further cash refund of approximately AUD $3.0m, which would complete the Company’s FY25 R&D rebate and provide additional non-dilutive funding.

Recce Pharmaceuticals' CEO, James Graham, said “This substantial rebate will go towards funding our R&D programs, both locally and overseas, including our ongoing Phase 3 Clinical Trial in Indonesia, and further domestic clinical programs. The funds received provide further confidence in our objectives and support the continued progression of Recce’s anti-infective portfolio. We appreciate the Australian Government’s ongoing commitment to supporting innovation and R&D, and we look forward to delivering important milestones as we advance our new class of synthetic anti-infectives.”

==> picture [543 x 63] intentionally omitted <==

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic AntiInfectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer antiinfectives: RECCE[®] 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE[®] 435 (R435) as an orally administered therapy for bacterial infections; and RECCE[®] 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s antiinfective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

==> picture [451 x 76] intentionally omitted <==